Compare · BRKR vs EYPT
BRKR vs EYPT
Side-by-side comparison of Bruker Corporation (BRKR) and EyePoint Inc. (EYPT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BRKR and EYPT operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- BRKR is the larger of the two at $8.66B, about 20.1x EYPT ($431.5M).
- Over the past year, BRKR is up 66.9% and EYPT is down 58.3% - BRKR leads by 125.2 points.
- BRKR has been more active in the news (19 items in the past 4 weeks vs 13 for EYPT).
- BRKR has more recent analyst coverage (22 ratings vs 15 for EYPT).
- Company
- Bruker Corporation
- EyePoint Inc.
- Price
- $56.82-0.07%
- $5.04+0.70%
- Market cap
- $8.66B
- $431.5M
- 1M return
- -9.67%
- -57.87%
- 1Y return
- +66.92%
- -58.25%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 19
- 13
- Recent ratings
- 22
- 15
Bruker Corporation
Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry solutions; analytical and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies; and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection. The company also provides X-ray instruments, atomic force microscopy instrumentation, fluorescence optical microscopy instruments, analytical tools for electron microscopes and X-ray metrology, defect-detection equipment for semiconductor process control, and spark optical emission spectroscopy systems, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments. In addition, it offers superconducting and non-superconducting materials and devices. The company serves academic and government research customers; pharmaceutical and biotechnology, diagnostics, chemical, food and beverage, clinical, nanotechnology, semiconductor, and other industrial companies; nonprofit laboratories; academic institutions and medical schools; contract research organizations; nonprofit and for-profit forensics, and environmental and clinical microbiology laboratories; agriculture, food, and beverage safety laboratories; hospitals and government departments; agencies; raw material manufacturers; and other businesses involved in materials analysis through direct sales forces, distributors, independent sales representatives, and other representatives. Bruker Corporation was incorporated in 1991 and is headquartered in Billerica, Massachusetts.
EyePoint Inc.
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor that is in Phase 1 clinical trials for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
Latest BRKR
- Chief Accounting Officer Bures Thomas was granted 4,035 shares, increasing direct ownership by 126% to 7,233 units (SEC Form 4)
- President BMID Group Pusch Wolfgang sold $197,614 worth of shares (3,473 units at $56.90) and was granted 3,120 shares, decreasing direct ownership by 3% to 9,801 units (SEC Form 4)
- EXECUTIVE VICE PRESIDENT, CFO Herman Gerald N was granted 15,794 shares and covered exercise/tax liability with 2,724 shares, increasing direct ownership by 13% to 111,354 units (SEC Form 4) to cover taxes
- EXEC VP&PRES BRUKER NANO INC. Munch Mark exercised 2,000 shares at a strike of $22.19, sold $115,200 worth of shares (2,000 units at $57.60) as part of a pre-agreed trading plan, was granted 14,443 shares and covered exercise/tax liability with 2,984 shares, increasing direct ownership by 9% to 134,806 units (SEC Form 4) (for tax liability)
- PRESIDENT & CEO Laukien Frank H was granted 29,463 shares and covered exercise/tax liability with 4,760 shares, increasing direct ownership by 0.06% to 38,507,043 units (SEC Form 4) to cover withholding tax
- PRESIDENT CALID Srega Juergen was granted 16,898 shares, increasing direct ownership by 11% to 174,625 units (SEC Form 4)
- PRES. & CEO, BRUKER BEST Prause Burkhard was granted 3,303 shares, increasing direct ownership by 13% to 28,461 units (SEC Form 4)
- EXEC VP&PRES BRUKER NANO INC. Munch Mark covered exercise/tax liability with 1,619 shares, decreasing direct ownership by 1% to 123,347 units (SEC Form 4) to satisfy withholding obligation
- PRESIDENT & CEO Laukien Frank H covered exercise/tax liability with 4,838 shares, decreasing direct ownership by 0.01% to 38,482,340 units (SEC Form 4) (tax withholding)
- EXECUTIVE VICE PRESIDENT, CFO Herman Gerald N covered exercise/tax liability with 1,410 shares, decreasing direct ownership by 1% to 98,284 units (SEC Form 4) (for tax liability)
Latest EYPT
- Chief Financial Officer Elston George acquired 5,000 shares, gifted 64,953 shares, received a gift of 64,953 shares and disposed of 5,000 shares, decreasing direct ownership by 65% to 32,517 units (SEC Form 4)
- Director Zaderej Karen L. bought $52,258 worth of shares (10,600 units at $4.93), increasing direct ownership by 28% to 49,100 units (SEC Form 4)
- EyePoint downgraded by Chardan Capital Markets with a new price target
- EyePoint downgraded by RBC Capital Mkts with a new price target
- EyePoint downgraded by H.C. Wainwright
- EyePoint downgraded by Cantor Fitzgerald
- EyePoint Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- EyePoint Announces Topline Data from LUGANO, the First of Two Pivotal Phase 3 Clinical Trials for DURAVYU™ 2.7mg in Wet AMD
- EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- SEC Form S-8 filed by EyePoint Inc.